Curis shares closed down 14% at $5.94 despite successfully consenting the first six patients in its TakeAim CLL trial combining emavusertib and zanubrutinib — surpassing internal enrollment projections and confirming a December 2026 preliminary data readout.

Key Highlights

  • Enrollment Milestone: First six patients consented in the TakeAim CLL study evaluating emavusertib plus zanubrutinib, surpassing internal projections with five patients on track to be dosed by late July 2026.
  • December 2026 Data Catalyst: Preliminary data from the CLL cohort remains on track for release in December 2026, providing a defined near-term efficacy readout for investors.
  • Differentiated Mechanism: Emavusertib's IRAK4 inhibition mechanism offers a complementary approach to BTK and BCL-2 inhibitors that dominate current CLL treatment algorithms.

The TakeAim CLL Trial: Clinical Context and Design

Curis successfully consented the first six patients in its TakeAim CLL clinical trial, which evaluates emavusertib — an IRAK4 inhibitor — in combination with zanubrutinib, BeiGene's BTK inhibitor marketed as Brukinsa. The enrollment pace beat the company's internal projections, with Curis on track to have five patients dosed by late July 2026. This is a meaningful operational achievement for a small-cap oncology company navigating the competitive clinical trial landscape for CLL, a disease with numerous active clinical programmes.

Chronic lymphocytic leukaemia is the most common form of leukaemia in adults in the Western world, representing a large and commercially significant oncology market. The current treatment landscape is dominated by BTK inhibitors — ibrutinib and acalabrutinib from AbbVie and AstraZeneca, and zanubrutinib from BeiGene — alongside the BCL-2 inhibitor venetoclax. Despite the effectiveness of these agents, a substantial proportion of patients develop resistance or intolerance, creating an ongoing unmet need for alternative mechanisms of action.

Emavusertib's IRAK4 inhibition mechanism is conceptually distinct from the BTK and BCL-2 inhibitors that define the current CLL treatment landscape. IRAK4 is a kinase involved in innate immune signalling pathways that can be co-opted by CLL cells to promote survival and proliferation, and preclinical evidence suggests that IRAK4 inhibition may have activity in both BTK-naive and BTK-resistant CLL. The combination with zanubrutinib is designed to test whether dual inhibition of the BCR signalling pathway (via BTK) and the innate immune signalling pathway (via IRAK4) produces additive or synergistic clinical benefit.

The December 2026 Data Readout as the Pivotal Catalyst

Management's reaffirmation that preliminary data from the CLL cohort is on track for December 2026 release provides investors with a concrete, near-term binary event around which to frame their investment thesis. December 2026 is approximately five months from the current date, making this a well-defined catalyst that is accessible within a single investment horizon for most institutional investors.

The nature of the expected December data is "preliminary" — likely to include safety data, early pharmacodynamic markers, and potentially some initial efficacy signals from the first patients dosed. Full efficacy data from a meaningful number of evaluable patients is unlikely to be available within this timeframe given the enrollment pace, but early clinical signals from IRAK4 inhibition in CLL are sufficient to materially influence investor perception of the programme's potential.

The melanoma cohort that Curis is also evaluating with emavusertib adds a second data stream that could provide supporting evidence for the drug's broader clinical utility. Multi-tumour type programmes with a shared mechanism of action allow early clinical signals in one indication to inform hypothesis generation and investor confidence in other indications.

Why the Stock Fell 14% Despite the Positive Enrollment News

The 14% decline in CRIS shares despite the enrollment milestone underscores the challenge small-cap oncology companies face in translating operational progress into sustained share price appreciation. Enrollment announcements — particularly for the first few patients in a trial — are necessary milestones on the path to data generation, but they are rarely sufficient to generate the kind of investor conviction that drives durable share price gains.

Several factors may have contributed to the selling despite the positive enrollment news. Profit-taking following recent strength is a common dynamic in small-cap biotech stocks that have appreciated ahead of a milestone announcement. Broader small-cap biotech sector selling pressure, independent of company-specific news, can overwhelm positive catalysts in individual stocks. The enrollment of six patients in an early trial is also a relatively modest milestone compared to the December 2026 data readout that will actually test the clinical thesis.

The investment case for Curis will be determined by the December 2026 preliminary data and whether the emavusertib plus zanubrutinib combination shows any hint of efficacy signals — particularly in BTK-resistant patients — that would justify advancing to a larger Phase 2 or Phase 3 study. The 14% decline from the pre-milestone price creates a potentially lower entry point for investors who want exposure to the December readout.

Frequently Asked Questions

Disclaimer: This article is for informational and educational purposes only and does not constitute financial or investment advice. Readers should conduct their own due diligence before making investment decisions.